April 2026 Biotech Catalysts to Watch
FDA decisions and clinical trial readouts expected in April 2026, each marked with what — if anything — a primary source confirms about it.
No date on this page has been confirmed against a primary source. Unsourced entries are AI-drafted from public information and can be wrong about whether an event is still upcoming; they are listed separately and show the expected window only. Verify against the FDA, the company, or ClinicalTrials.gov before acting on any of them. 3 of 9 link to the ClinicalTrials.gov record for the program behind them — the registry confirms that the program exists, not the date.
9 catalysts shown
NTLA-2002 Phase 3 interim data in hereditary angioedema
NTLA-2002 · Hereditary angioedema (HAE)
Program confirmed on ClinicalTrials.gov · 2026-09-05 · the date itself is unverified
Funded through this catalyst. Cash reaches roughly Q4 2027 on the disclosed figures, about 6 quarters past this Q2 2026 catalyst — the readout is funded without a raise.
Sponsor record: 2 of 6 late-stage studies registered by Intellia Therapeutics were stopped early. Trials stop for many reasons — see the company profile for each one.
Why it matters
First pivotal readout for an in vivo CRISPR gene editing therapy in HAE. Phase 1/2 showed 95% reduction in HAE attacks from a single IV infusion. Phase 3 will determine if this becomes the first in vivo CRISPR medicine ever approved.
Primary endpoint is reduction in investigator-confirmed HAE attacks. Phase 1/2 bar is 95% reduction. Any result above 80% would likely support approval. This is also a safety readout — long-term gene editing safety will be heavily scrutinized.
AI-drafted context, not individually reviewed.
SRP-9001 (Elevidys) confirmatory Phase 3 EMBARK study updated analysis
Elevidys (delandistrogene moxeparvovec) · Duchenne muscular dystrophy
Program confirmed on ClinicalTrials.gov · 2026-09-05 · the date itself is unverified
Sponsor record: 8 of 28 late-stage studies registered by Sarepta Therapeutics were stopped early. Trials stop for many reasons — see the company profile for each one.
Why it matters
Updated confirmatory data for Sarepta's gene therapy for Duchenne muscular dystrophy. Elevidys received accelerated approval in 2023 but needs confirmatory data to maintain its marketing authorization. Safety concerns have clouded the commercial picture.
Functional improvement on NSAA (North Star Ambulatory Assessment) vs. placebo. The earlier interim analysis was mixed. This longer-term readout is critical. If confirmatory data is weak, FDA could pull accelerated approval.
AI-drafted context, not individually reviewed.
BEAM-101 updated Phase 1/2 data in sickle cell disease at ASGCT
BEAM-101 · Sickle cell disease
Program confirmed on ClinicalTrials.gov · 2026-09-05 · the date itself is unverified
Why it matters
Updated clinical data for Beam's base editing therapy for sickle cell disease, presented at the American Society of Gene & Cell Therapy meeting. Base editing is 'next-gen CRISPR' — it makes precise single-letter DNA changes without cutting both strands.
Look for fetal hemoglobin induction levels and clinical outcomes (vaso-occlusive crises). Beam needs to show their base editing approach is at least comparable to CRISPR Therapeutics' Casgevy, which sets the bar as the approved therapy.
AI-drafted context, not individually reviewed.
Unconfirmed watchlist
No primary source has been found for these yet. They are AI-drafted from public information, shown with the expected window rather than a day, and may already have happened or moved. Treat them as prompts to check the company's guidance, not as dates.
Phase 3 interim analysis of povetacicept in IgA nephropathy
Povetacicept · IgA nephropathy (kidney disease)
Unverified — date is AI-generated and has not been checked against a primary source.
Sponsor record: 17 of 156 late-stage studies registered by Vertex Pharmaceuticals were stopped early. Trials stop for many reasons — see the company profile for each one.
Why it matters
Vertex's kidney disease drug povetacicept hits a key interim analysis. Phase 2 showed unprecedented proteinuria reduction. If Phase 3 confirms, this becomes Vertex's biggest non-CF franchise and could support accelerated approval.
Interim data should confirm proteinuria reduction in a larger population. Look for consistency with Phase 2 results showing >50% proteinuria reduction. Positive data likely triggers accelerated filing.
AI-drafted context, not individually reviewed.
Voyage Phase 3 topline results for MM120 in generalized anxiety disorder
MM120 (lysergide D-tartrate) · Generalized anxiety disorder (GAD)
Unverified — date is AI-generated and has not been checked against a primary source.
Why it matters
The first of two pivotal trials testing a psychedelic-derived medicine for anxiety. A single supervised dose of MM120 showed 12+ weeks of anxiety relief in Phase 2. This readout will determine whether psychedelic medicine for psychiatry is real or hype.
Binary event. Success (statistically significant HAM-A reduction vs placebo at 12 weeks) sends MNMD up 50-100%+. Failure sends it down 50-70%. Key risk: high placebo response rates in anxiety trials. Watch the p-value and effect size closely.
AI-drafted context, not individually reviewed.
mRNA-1010 Phase 3 data for standalone flu vaccine
mRNA-1010 · Seasonal influenza
Unverified — date is AI-generated and has not been checked against a primary source.
Why it matters
Moderna's standalone mRNA flu vaccine faces its pivotal moment. If it demonstrates superiority over traditional egg-based flu vaccines, it would validate mRNA technology beyond COVID and open a $7B+ annual market.
The key question is superiority, not just non-inferiority. If mRNA-1010 merely matches existing flu vaccines, the commercial case weakens. Look for meaningfully higher seroconversion rates and geometric mean titers, especially in elderly populations where current vaccines underperform.
AI-drafted context, not individually reviewed.
Amvuttra (vutrisiran) HELIOS-B cardiovascular outcome data update
Amvuttra (vutrisiran) · ATTR cardiomyopathy
Unverified — date is AI-generated and has not been checked against a primary source.
Sponsor record: 6 of 45 late-stage studies registered by Alnylam Pharmaceuticals were stopped early. Trials stop for many reasons — see the company profile for each one.
Why it matters
Updated cardiovascular outcomes data for Alnylam's Amvuttra in ATTR cardiomyopathy. HELIOS-B is the trial that demonstrated mortality benefit — this update provides longer follow-up. Critical for the label expansion and commercial trajectory.
Longer follow-up should confirm the mortality benefit seen in the primary analysis. Any erosion of the survival curve would concern investors. Consistent data supports a multibillion-dollar ATTR franchise.
AI-drafted context, not individually reviewed.
VK2735 Phase 3 VENTURE enrollment update and potential interim look
VK2735 · Obesity
Unverified — date is AI-generated and has not been checked against a primary source.
Tight against cash. Cash reaches roughly Q2 2027 on the disclosed figures, about 4 quarters past this Q2 2026 catalyst. A disappointing result would leave little room to fund what comes next.
Why it matters
Viking provides an update on enrollment progress for the pivotal VENTURE obesity trial. Fast enrollment would signal strong investigator and patient interest. An early interim look, if triggered, would provide the first Phase 3 efficacy signal.
Enrollment pace is a leading indicator. >75% enrolled would suggest topline data in early 2027. Any interim efficacy data would be a major catalyst. The stock moves on even enrollment updates in the obesity space.
AI-drafted context, not individually reviewed.
BNT327 (PD-L1 x VEGF bispecific) Phase 2 expansion data in NSCLC
BNT327 · Non-small cell lung cancer
Unverified — date is AI-generated and has not been checked against a primary source.
Sponsor record: 7 of 57 late-stage studies registered by BioNTech were stopped early. Trials stop for many reasons — see the company profile for each one.
Why it matters
BioNTech presents updated data for its bispecific antibody targeting both PD-L1 and VEGF in lung cancer. This represents BioNTech's push beyond vaccines into oncology — the area that will define its post-COVID future.
Response rates and progression-free survival data in NSCLC patients. BioNTech needs to demonstrate meaningful clinical activity to justify the $15B+ it's investing in its oncology pipeline beyond vaccines.
AI-drafted context, not individually reviewed.
Market context
The biotech sector enters April 2026 with cautious optimism. The XBI biotech index recovered significantly from its 2023-2024 lows, driven by large-cap M&A activity and several successful Phase 3 readouts. However, macro headwinds persist: higher-for-longer interest rates pressure pre-revenue biotechs, and the FDA's staffing turmoil under HHS leadership changes has created regulatory uncertainty. The GLP-1/obesity space remains the hottest subsector, with Lilly and Novo reporting massive sales growth. Gene editing and cell therapy companies are in a crucial proving period as multiple programs hit Phase 3 milestones. April is loaded with potential stock-moving events, particularly in the gene editing (NTLA), psychedelic medicine (MNMD), and rare disease (PRAX, SRPT) spaces.
Conferences this period
AACR Annual Meeting 2026
April 11-16, 2026
ASGCT Annual Meeting 2026
April 22-25, 2026
Sponsored
Trade upcoming biotech catalysts commission-free on WebullAffiliate link — we may earn a commission at no cost to you
Want one of these readouts explained in writing?
Name a catalyst from this calendar and get a written breakdown of what the trial actually measures, what success and failure look like, and where the endpoint, safety, and financing risk sits — in 3 business days, for $249.
Get the free April 2026 catalyst briefing
Receive the next weekly briefing with the biggest upcoming catalysts, date changes, and plain-English context.
Free weekly biotech briefing. No spam. We only use this address for the briefing. By subscribing, you agree to our Privacy Policy and Terms.
No financial advice. Educational research only. Affiliate links may earn compensation.